54例胰体尾癌根治术后生存率分析

目的：分析影响胰腺体尾癌术后生存因素。方法：随访我科2002年至2006年间54例根治性胰体尾癌切除术病人,用寿命表法进行生存率分析,并研究与预后相关的危险因素。结果：69例病人的1年生存率为68.8%,2年生存率为56.1%,3年生存率为34.2%,中位生存期23.6月。性别、年龄与术后生存率无关（P〉0.05）。有局部淋巴结转移、神经侵犯病人的术后1年生存率显著低于无局部淋巴结转移、无神经侵犯者（P值均〈0.05）。胰体尾联合脾切除术的不同残端处理方式间的生存率差异无统计学意义（P〉0.05）。结论：胰体尾癌局部淋巴结转移和神经侵犯情况与其预后之间有密切联系。     

Renal cell carcinoma metastatic to the pancreas: Results of surgical management

Metastatic tumors to the pancreas are uncommon. Renal cell carcinoma is one of the few tumors known to metastasize to the pancreas. The purpose of the current report is to evaluate the surgical management and long-term outcome of patients with metastatic renal cell carcinoma. A retrospective review of patients undergoing pancreatic resection for renal cell carcinomas metastatic to the pancreas or periampullary region between April 1989 and May 1999, inclusive, was performed. Time from initial presentation, other metastatic sites, surgical outcomes, and long-term survival were evaluated. During the 10-year time period, 10 patients underwent pancreatic resection for renal cell carcinoma metastases. Ofthose, six underwent pancreaticoduodenectomy and two underwent distal pancreatectomy, whereas the two remaining patients underwent total pancreatectomy for extensive tumor involvement throughout the entire gland. The mean time from nephrectomy for resection of the primary tumor to reoperation for periampullary recurrence was 9.8 years (median 8.5 years). The range was 0 to 28 years, with one patient presenting with a synchronous metastasis. The mean age of the patients was 61.2 years with 60% of patients being male and 90% being white. Pathologic findings included histologically negative lymph nodes and negative surgical margins in all patients. One patient had tumor involving the retroperitoneal soft tissue, but final margins were negative. The mean live patient follow-up was 30 months (median =1.5 months), with eight patients remaining alive. The Kaplan-Meier actuarial 5-year survival was 75%, with the longest survivor still alive 117 months following resection. The patient with retroperitoneal soft tissue involvement died 4 months after resection. The pancreas is an uncommon site of metastasis for renal cell carcinoma, typically occurring years after treatment of the primary tumor. When the metastatic focus is isolated and the tumor can be resected in its entirety, patients can experience excellent S-year survival rates. The current report suggests that pancreatic metastases from renal cell carcinoma should be managed aggressively with complete resection when possible. Presented at the Forty-First Annual Meeting of The Society for Surgery of the Alimentary Tract, San Diego, Calif., May 2l–24, 2000.     

Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival

PURPOSE: The pancreas is an uncommon site of metastasis from renal cell carcinoma, comprising 2% of pancreatic tumors removed in sizable series of operations. To our knowledge the role of operative resection in the setting of metastatic malignancy to the periampullary region has not yet been defined. We reviewed the records of 6 women and 2 men who underwent pancreatic resection due to malignancy and analyzed various prognostic factors. MATERIALS AND METHODS: Between 1985 and 1995, 269 patients underwent pancreatic resection for malignancy at our hospitals, including 150 (56%) for pancreatic duct cancer, 65 (24%) for carcinoma of the ampulla, 27 (10%) for distal bile duct cancer, 19 (7%) for duodenal carcinoma and 8 (3%) for renal cell carcinoma metastasis. We reviewed the records of these latter 8 cases, and analyzed demographics, primary tumor type, disease-free interval, resection type, concomitant other organ resection, histological examination of the specimen, morbidity, adjuvant therapy and survival. RESULTS: Pancreatic metastasis of renal cell carcinoma was managed by duodenopancreatectomy in 5 patients and total pancreatectomy in 3. There were no perioperative deaths. Mean tumor size in cases of a solitary pancreatic metastasis was 4 cm. (range 1.5 to 8). In the 3 patients treated with total pancreatectomy there were 2, 5 and 3 pancreatic metastases, respectively. Pathological examination revealed negative lymph nodes in all cases. Mean survival was 48 months. At study end 6 patients were alive at 24, 26, 30, 46, 84 and 88 months, while 2 died at 13 and 70 months, respectively. CONCLUSIONS: We advocate aggressive surgical resection when possible. Surgical removal of metastatic lesions prolongs survival but radical lymph node dissection is not mandatory. We also recommend careful long-term followup of patients with a history of renal cell carcinoma.     

Malignant Nonfunctioning Endocrine Tumors of the Pancreas: Predictive Factors for Survival after Surgical Treatment

BACKGROUND: There are scant studies that have analyzed the prognostic factors for malignant nonfunctioning endocrine tumors of the pancreas. We identified the predictive factors associated with long-term survival after surgical resection for malignant nonfunctioning endocrine tumors. METHODS: Among the 25 patients seen at our hospital with a diagnosis of malignant nonfunctioning endocrine tumor, a review was performed on 22 of these patients who were surgically treated at our institution over the last 10 years. The following factors were evaluated for disease-specific mortality: age, gender, tumor location, tumor size, histological differentiation, status of the resection margin, and status of lymph node involvement. RESULTS: Tumor recurrence was noted in 9 cases (40.9%) among the 22 operated patients. Of the 9 recurrent cases, 7 patients (77.8%) had liver metastases. The median follow-up period was 24.8 (range: 3.7-121.4) months. The overall actuarial 1-, 2- and 5-year survival rates were 84.1%, 72.5%, and 52.8%, respectively. The factor shown to have a favorable independent prognostic significance was a negative resection margin (odds ratio = 19.44, 95% confidence interval = 1.22-310.54, P = 0.036). CONCLUSIONS: Definitive surgical resection of the primary tumor was a predictor of long-term survival after surgical resection for malignant nonfunctioning endocrine tumor.     

血管内皮生长因子C与胰腺癌根治术后复发的相关性研究

目的 探讨血管内皮生长因子C(VEGF-C)表达及多种临床病理因素在预测胰腺癌根治术后复发的价值.方法 应用Envision免疫组化法测定47例胰腺癌根治性切除标本中胰腺癌组织和自身胰腺正常组织中VEGF-C的表达.通过Kaplan-Meier生存分析和Cox风险比例模型,评估VEGF-C和各临床病理因素对胰腺癌根治术后复发的影响.结果 VEGF-C在胰腺癌组织中的表达比例及其在自身正常胰腺组织中的表达比例分别为29例(61.7%)、7例(14.9%),VEGF-C在胰腺癌组织中的表达比例明显高于其在自身正常胰腺组织中的表达(P=0.018).胰腺癌根治术后患者无病中位生存期为11.9个月,平均为(18.4±2.4)个月.1年、2年、3年累计无病生存率分别为46.8%、23.4%和14.4%.VEGF-C的表达与淋巴结转移有显著的相关性(P=0.036).单因素生存分析显示VEGF-C(P=0.020)、肿瘤直径(P=0.013)、年龄(P=0.057)、术后辅助化疗(P=0.017)与无病生存期明显相关.Cox回归多因素分析显示,VEGF-C(P=0.009),肿瘤直径(P=0.010)、术后辅助化疗(P=0.017)是胰腺癌根治术后患者无病生存期独立的预后因素.结论 VEGF-C在胰腺癌组织中表达明显增高,VEGF-C的表达与淋巴结转移有显著的相关性,VEGF-C可作为判断胰腺癌根治术后患者无病生存期的独立指标.

Abstract：

Objective To investigate the prognostic value of vascular endothelial growth factor C (VEGF-C) and clinicopathologic indexes in predicting recurrence following curative resection of pancreatic cancer. Methods The expressions of VEGF-C of 47 patients who underwent curative resection for curative pancreatic cancer resection were detected by Envision immunohistochemical methods. The effects of VEGF-C and clinicopathologic indexes on recurrence were assessed by the Kaplan-Meier and Cox proportional hazards model. Results The positive rates of VEGF-C were 61. 7% in = 29) and 14. 9%(n = 7), respectively, in pancreatic cancer and normal pancreatic tissues. The positive expression of VEGF-C in pancreatic carcinoma was obviously higher than the normal pancreatic tissues (P = 0. 018). The median disease-free survival time was 11. 9 months, the average disease-free survival time was 18. 4 + 2. 4 months, and the cumulative 1-year, 2-year and 3-year actuarial recurrence free survival rates were 46. 8%, 23. 4%, 14. 4%, respectively. There was a significant correlation between the VEGF-C expression and lymph node metastasis in pancreatic cancer (P = 0. 036). On Kaplan-Meier analysis, VEGF-C (P = 0. 020), tumor diameter (P = 0. 013), age (P = 0. 057) and adjuvant chemotherapy (P=0. 017) were associated with disease-free survival time. Multivariate analysis showed VEGF-C (P = 0. 009), tumor diameter (P = 0. 010) and adjuvant chemotherapy (P = 0. 017)were independent prognostic factors of disease-free survival after surgery for pancreatic cancer.Conclusion The expression of VEGF-C was higher in pancreatic cancer, and VEGF-C was correlated with lymph node metastasis. VEGF-C was the biomarker that independently predicted disease-free survival after surgery for pancreatic cancer.     

Number of Lymph Node Metastases Is a Significant Prognostic Factor in Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (IHCC) is a rare primary hepatic tumor. Outcomes after resection and the use of lymph node dissection have not been well described. From a prospective database, we identified 53 patients with IHCC who underwent exploration between April 1983 and March 2004. Hepatic resection was performed in 44 patients, 30 of whom underwent lymph node dissection. Clinicopathological features and outcomes were analyzed. The actuarial 1-year survival was 66.2% in resected patients, compared to 0% in unresectable patients (p < 0.0001), with a 50% overall survival of 21.5 months and 3.1 months, respectively. The actuarial 3-year and 5-year overall survival rates in resected patients were 38.3% and 26.3%, respectively. Univariate analysis revealed that factors associated with poor overall survival included multiple tumors, extrahepatic bile duct involvement, noncurative resection, and involvement of lymph nodes. Multivariate analysis in resected patients revealed that multiple tumors (p < 0.0074) and non-curative resection (p = 0.0068) were significant risk factors for poor overall survival. The survival rate in patients with three or more positive nodes was significantly lower than in those with fewer than three (p < 0.0001). Three patients with solitary tumors and one or two involved lymph nodes have survived beyond 4 years after extended lobectomy with systemic lymphadenectomy. Curative resection, single tumor, and fewer than two lymph node metastases were prognostic factors for good outcome. Curative resection with lymph node dissection improved survival in patients with no more than two positive lymph nodes.     

Prospects for standardization of surgical procedures for carcinoma of the pancreas

Since physicians need to guarantee the efficacy of medical therapy for patients, therapies for patients with cancer should be standardized to some extent. Carcinoma of the pancreas has the highest death rate of all cancers, with a resection rate as low as about 25% to 30% and a 5-year survival rate of around 9%. It is very difficult in such a situation to standardize the surgical strategy for carcinoma of the pancreas. Because pancreatic cancer is a general disease, the treatment strategy should include not only complete surgical resection but also local control methods with intraoperative radiation, prevention of liver metastasis, development of effective anti-cancer drugs, etc. Major progress in therapy for pancreatic carcinoma may be expected in the near future by with the cumulative use of effective therapies. Standard resection and extended resection: For carcinoma of the head of the pancreas, pancreaticoduodenectomy with regional lymph node dissection is performed in Japan, as is extended resection with thorough lymph node dissection of the retroperitoneal and paraaortic region. However, so far the prognosis of patients who undergo extended resection is not better than those who undergo standard resection. A randomized controlled trial of the two types of resection is now being conducted and its results are awaited. For carcinoma of the body and tail of the pancreas, distal pancreatectomy and splenectomy with lymph node dissection is performed if hematogenous or massive lymph node metastasis or direct invasion of the large vessels has not occurred. The Appleby procedure is performed in some cases. Reconstruction and complications of surgical procedures of carcinoma of the pancreas: It appears that a decrease in complications and a lower death rate have been achieved due to pancreaticoduodenectomy rather than due to the extent of lymph node dissection. In particular, progress in anastomosis techniques of the pancreas and intestine and in perioperative control has been marked. For prevention of complications, it is important that absorbable synthetic sutures be used in the pancreaticojejunal anastomosis, that the cut end of the pancreas be sutured and covered by the jejunum without dead space, and that the stent tube be inserted into the main pancreatic duct. The pancreaticojejunal anastomosis should be bordered by the greater omentum. This technique will prevent both the spread of the pancreatic juice into the intraabdominal cavity and rupture of the blood vessels, which can cause fatal postoperative bleeding. Sufficient intraabdominal drains should be in place, especially around the pancreaticojejunal anastomosis. Radiochemotherapy: There are no effective anticancer drugs for the treatment of carcinoma of the pancreas. It was reported that low-dose 5-fluorouracil and cisplatin (5-FU and CDDP) and gemcitabine plus either 5-FU, epirubicin, or CDDP has some effect. The efficacy of intraoperative radiotherapy has not been confirmed. It is not apparent whether radiochemotherapy is superior to surgery. Curable pancreatic carcinoma: Intraductal papillary-mucinous tumors of the pancreas (IPMT) take their name from the histological feature of mucin production and correspond to so-called mucin-producing tumors of the pancreas. This tumor is classified into two types, the main pancreatic duct type and the branch type. About 90% of the main pancreatic duct type and 20% of the branch type are malignant. The branch type of IPMT resembles a bunch of grasps in imaging procedures. Approximately 60% of cases with the branch type of IPMT can be followed up without surgery. Since the prognosis of IPMT is fairly good and the 5-year survival after surgery is about 70% to 80%, limited resection of the pancreas with organ preservation is under investigation. Mucinous cystic tumors of the pancreasin are characterized by development in the body and tail of the pancreas in middle-aged women, with histological ovarian-type stroma in the wall of the tumor, and round cystic lesions with a fibrous capsule containing multiple cystic components of various sizes, which resembles a Chinese citron upon imaging procedures. Surgery should be performed if such a diagnosis is made.     

从胰腺癌患者的长期生存看预后因素及治疗模式

Pancreatic cancer has the characteristics of high malignancy, early dissemination within the pancreas,extrapancreatic nerve plexus invasion, lymph node metastasis and vascular invasion. The 5-year survival rate of pancreatic cancer patients was under 5% even for those who had undergone surgical resection. Based on the review of the literatures including 42 pancreatic cancer patients who survived for 5-20 years after the operation, we concluded that curative resection of pancreatic cancer was still a reliable means in achieving long-term survival; factors influencing the results of resection of pancreatic cancer were lymph nodes involvement, poor differentiated tumor, extrapancreatic nerve plexus invasion, tumor size, residual tumor, curative resection and adjuvant chemotherapy; early diagnosis, aggressive surgery for patients with indications of resection, appropriate surgical procedure and postoperative adjuvant chemotherapy are essential factors to ensure a long term survival of patients with pancreatic cancer.     

Surgery and the management of peripheral lung tumors adherent to the parietal pleura.

Among 37 patients with peripheral T3 lung lesions, preoperative clinical and imaging evidence was suggestive of T3 disease in 28 and of T2 disease in nine. Intraoperatively, the T2 designation was changed to T3 on the basis of adherence of the tumor to the parietal pleura. All had mediastinoscopy followed by resection and complete lymph node dissection. There were 17 lobectomies and 20 pneumonectomies. The chest wall was resected in continuity with the lung in 21 patients, and in 16 only an extrapleural resection was done. Follow-up was completed in all patients (range 2 to 14 years, median 7 years). The 5-year actuarial survival rate for all patients was 30%. As expected, the presence of lymph node metastasis affected the 5-year actuarial survival rate: N0 = 41%; N1 = 29%, and N2 = 0%. Histologic examination of the resected specimen confirmed a T3 lesion in 30 patients. The tumor was removed completely in 100% of patients whose chest wall was resected in continuity with the lung but in only 31% in whom an extrapleural resection was done. In the absence of lymph node metastasis, the 5-year survival rate of patients after en bloc resection of the chest wall was 50% compared with 33% for those with extrapleural resection (p less than 0.05). The finding of a peripheral lung tumor adherent to the parietal pleura indicates, in most instances, extension through the parietal pleura. When tumor is firmly adherent to the parietal pleura, an en bloc resection of the chest wall rather than an extrapleural dissection should be performed. This assures complete tumor removal and improves the probability of long-term survival.     

从胰腺癌患者的长期生存看预后因素及治疗模式

胰腺癌恶性程度高,具有早期胰腺内播散,胰腺外神经丛侵犯,淋巴结转移与血管侵犯的特点.即使外科切除,大部分患者5年生存率仍<5%. 1长期生存的特征     

Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer

Well-differentiated islet cell tumors can be associated with aggressive biology, resulting in early metastases to the liver. This study was carried out to determine whether survival for patients with malignant islet cell tumors and synchronous liver metastases is affected by complete surgical resection. Thirty-one patients with synchronous liver metastases from islet cell cancer underwent surgical exploration with the intent for complete tumor resection, and all patients underwent resection of the pancreatic primary. The patients were divided into two groups, those with resectable versus unresectable liver metastases. Twenty-six of 31 (84%) patients underwent complete resection of both the primary tumor and all liver metastases, and 5 (16%) patients underwent only complete resection of the pancreatic primary without liver resection. To extirpate the primary tumor, a pancreaticoduodenectomy was performed in 11 of the 26 (42%) completely resected patients and in 4 of the 5 (80%) incompletely resected patients, P = NS. The remainder of the patients underwent distal pancreatectomy. There were no statistical differences in primary tumor size, lymph node metastases, or adjuvant treatments between patients with resected and unresected liver metastases. The median overall survival for the completely resected group was 78 months, longer than the 17 months for the group with unresectable liver metastases (P = 0.06). Complete tumor resection (or the tumor biology that allows such complete resection) affords a survival advantage to patients with metastatic islet cell tumors of the pancreas. Patterns of liver metastases from islet cell tumors, specifically multiple bilobar metastases that are not amenable to resection and/or ablation, predict a poor outcome despite resection of the primary pancreatic tumor. Presented at the Thirty-Eighth Annual Meeting of The Pancreas Club, New Orleans, LA., May 16, 2004.     

Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

OBJECTIVE: To determine long-term survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma and to identify clinical factors associated with long-term survival. SUMMARY BACKGROUND DATA: The prognosis for long-term survival even after potentially curative resection for pancreatic adenocarcinoma is thought to be poor. Clinical factors determining short-term survival after pancreatic resection are well studied, but prognostic factors predicting long-term survival with a potential for cure are poorly understood. METHODS: A case-control study was conducted of 357 patients who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 1981 and 2001. Histologic specimens were reanalyzed to confirm diagnosis. Follow-up was at least 5 years or until death. RESULTS: There was an improved survival throughout the observation period (P = 0.004). We found 62 actual 5-year survivors of whom 21 patients survived greater than 10 years, for a 5- and 10-year survival rate of 18% and 13%, respectively. Cohort analysis comparing patients with short-term (<5 years, n = 295) and long-term (> or =5 years, n = 62) survival showed that more advanced disease (greatest tumor diameter, lymph node metastasis) and decreased serum albumin concentration were unfavorable for long-term survival (all P < 0.05). In contrast, the extent of resection and more aggressive histologic features did not correlate with long-term survival (all P > 0.05). En-bloc resection (P = 0.005) but not resection margin status (P > 0.05) was associated with long-term survival. Adjuvant chemoradiation therapy did not significantly influence long-term survival. Multivariate analysis identified lymph node status (OR 0.36, 95% CI 0.14-0.89, P = 0.03) as a prognostic factor for long-term survival. Five-year survival was no guarantee of cure because 16% of this subset died of pancreatic cancer up to 7.8 years after operation. CONCLUSION: Pancreatoduodenectomy for adenocarcinoma in the head of pancreas can provide long-term survival in a subset of patients, particularly in the absence of lymph node metastasis. One of 8 patients can achieve 10-year survival with a potential for cure.     

区域淋巴结廓清在胰头癌根治术中的应用

目的 探讨区域淋巴结廓清结合胰十二指肠切除术治疗胰头癌的有效性和安全性。方法 在常规胰十二指肠切除术(Whipple)基础上，进行区域淋巴结廓清，同时清除从腹腔动脉干至肠系膜下动脉的后腹膜组织，重点清除肠系膜根部淋巴结(14组)、肝十二指肠韧带内淋巴结(12组)、腹主动脉旁淋巴结(16组)、以及肝动脉旁(8组)、腹腔动脉旁(9组)淋巴结。结果 53例胰头癌病人施行了以区域淋巴结廓清为重点的胰头癌根治术，其中有3例合并切除了受浸润的一段肠系膜上静脉。手术无严重并发症发生，病人均痊愈出院。53例病人中有38例(72％)发生淋巴结转移，其中以胰头后(13组)、肠系膜根部(14组)发生率最高；14组淋巴结中各亚组转移率较为平均；发生第二站淋巴结转移的比例高达63％；肿瘤大小与淋巴结转移不成正比，小于2cm的肿瘤已经有第二站淋巴结的转移；术后1，2，3，5年生存率分别为70％，52．8％，26．7％，17．8％。结论 胰头癌的淋巴结转移呈现发生早、播散远和以肠系膜根部等部位为重点的特征，以区域淋巴结廓清为重点的胰头癌根治术能较为彻底地清除区域内淋巴结以及后腹膜组织，有助于保证手术的彻底性。     

局部切除胰体尾联合血管切除重建治疗晚期胰腺癌的疗效分析

目的:探讨局部切除胰体尾联合血管切除重建手术治疗晚期胰腺癌的效果。方法:将2010年—2012年收治的58例胰腺体部及体尾部晚期胰腺癌患者分为观察组和对照组,观察组患者采用局部切除胰体尾联合血管切除重建手术治疗后配合化疗,对照组仅接受化疗,比较两组患者的临床治疗效果与生存情况并分析预后因素。结果:两组患者的一般资料具有可比性;与对照组比较,观察组的客观有效率(44.9%vs.6.9%)、疾病控制率(82.8%vs.55.2%)明显升高(均P0.05);半年生存率(79.3%vs.48.3%)、1年生存率(55.2%vs.17.2%)、平均生存时间(17.6个月vs.10.3个月)、总生存率和无进展生存率均明显增加(均P0.05);两组患者的不良反应发生率差异无统计学差异(P0.05);单因素分析结果显示,肿瘤分期、有无淋巴/血管转移是胰腺癌患者无进展生存的影响因素(均P0.05)。结论:对于可以采取手术治疗的晚期胰腺癌患者而言,采用局部切除胰体尾联合血管切除重建手术疗效良好,可推荐应用。     

Prognostic factors for survival in patients with T3 laryngeal carcinoma.

In a total of 511 patients with T3,N0-3,M0 laryngeal carcinoma, 24 possible prognostic factors were analyzed retrospectively. The factors were age, sex, mode of treatment, duration of several clinical symptoms, the presence of sore throat, otalgia, dyspnea, and dysphagia, previous tracheotomy, tumor extension, lymph node status (five items), histologic grading, smoking habits, and alcohol intake. For 300 patients in whom surgery was part of the primary treatment, pathologic staging of the primary tumor and of lymph nodes in neck dissection specimens, cartilage invasion, radicality of the operation, differentiation grade, and subglottic extension ware also evaluated. In a univariate analysis for the whole group, tumor extension (limited to the glottic region), lymph node status (clinically palpable lymph nodes, cytologically confirmed positive lymph nodes), level of lymph node metastasis (high and midjugular site), histologic grading (poor differentiation grade), and treatment modality (planned combined therapy) were considered to be prognostic factors of corrected actuarial survival. In the group that underwent surgery, all factors derived from specimens of the larynx and neck dissections had prognostic significance. Multivariate analysis revealed that the glottic site of the tumor, the presence of cyto- and histopathologically proven metastatic lymph nodes, pretreatment tracheotomy, positive resection margins, and planned combined treatment had a significant influence on corrected actuarial survival.     

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis

Background

Studies to identify preoperative prognostic variables for pancreatic neuroendocrine tumor (PNET) have been inconclusive. Specifically, the prevalence and prognostic significance of radiographic calcifications in these tumors remains unclear.

Methods

From 1998 to 2009, a total of 110 patients with well-differentiated PNET underwent surgical resection at our institution. Synchronous liver metastases present in 31 patients (28%) were addressed surgically with curative intent. Patients with high-grade PNET were excluded. The presence of calcifications in the primary tumor on preoperative computed tomography was recorded and correlated with clinicopathologic variables and overall survival.

Results

Calcifications were present in 16% of patients and were more common in gastrinomas and glucagonomas (50%), but never encountered in insulinomas. Calcified tumors were larger (median size 4.5 vs. 2.3?cm, P?=?0.04) and more commonly associated with lymph node metastasis (75 vs. 35%, P?=?0.01), synchronous liver metastasis (62 vs. 21%, P?P?P?=?0.01) and size (P?P?=?0.04), but not in the presence of radiographic calcifications.

Conclusions

Calcifications on preoperative computed tomography correlate with intermediate grade and lymph node metastasis in well-differentiated PNET. This information is available preoperatively and supports the routine dissection of regional lymph nodes through formal pancreatectomy rather than enucleation in calcified PNET.     

The primary tumour resection with extended D3 lymph node dissection, metastases of synchronous metastatic colorectal cancer

The progress in colorectal cancer treatment of IV stage that was shown in last decades was mainly due to modern chemotherapy schemes and aggressive surgical approach towards distant metastatic lesions. Meanwhile less attention is paid to primary tumour treatment - the questions of necessity and volume of its resection are still open. The AIM of this study was to evaluate safety and oncologic effectiveness of primary tumour resection with D3 lymph node dissection in synchronous metastatic colorectal cancer. Patients with colorectal cancer and synchronous metastatic lesion of distant organs who underwent surgical resection of primary tumour were chosen from prospectively collected department database. The analysis of short-term and long-term results of resections with and without extended D3 lymph node dissection and prognostic factors affecting overall survival was carried out. From 2006 to 2011 total of 190 patients underwent primary tumour resection, 157 (82.6%) among them - with extended D3 lymph node dissection. Twenty one patient (11%) developed postoperative complications that required reintervention, 30-days mortality rate was 2.6%. Three-year cumulative overall survival was 37%, median survival - 22 months (25 months with extended lymph node dissection and 4 months without, p<0.001). Univariate analysis revealed following statistically significant prognostic factors improving overall survival: metastatic lesions in one distant organ, solitary haematogenous nodes, extended D3 lymph node dissection, postoperative chemotherapy, resection of metastatic lesions. Removal of primary tumour with extended lymph node dissection in metastatic colorectal cancer doesn't increase the number of postoperative complications and mortality. Performing D3 lymph node dissection favours increase of median survival and is a significant prognostic factor influencing outcomes.     

Surgical treatment for carcinoma of the pancreas. Experience in 272 patients

We have reviewed the prognoses in 272 patients with carcinoma of the pancreas who were treated in our department during a 25 year period. Thirty-eight patients with carcinoma of the head of the pancreas (22.1 percent) and 7 patients with carcinoma of the body and tail of the pancreas underwent tumor resection. The 5 year survival rate was 8.1 percent for patients who had resection of carcinoma of the head of the pancreas. The postoperative survival period varied greatly with the presence or absence of lymph node metastasis and pancreatic capsular invasion. There were patients with small pancreatic tumors of 2 cm or less who already had lymph node and vessel metastases. Early lymphatic and hematogenous metastases were the characteristic modes of progression of carcinoma of the pancreas. Combined therapeutic modalities are essential for treatment.     

Laparoscopic pancreaticoduodenectomy: technique and outcomes

BACKGROUND: We describe our experience with laparoscopic pancreaticoduodenectomy, including 5-year actuarial survival rates. STUDY DESIGN: This is a retrospective study of selected patients who underwent laparoscopic pancreaticoduodenectomy at a single center between 1998 and 2006. We have described the salient features of our technique and followup protocol. Patient characteristics, histologic variety of the tumor, resection margins, morbidity, mortality, and actuarial survival rates were studied. RESULTS: The procedure could be completed laparoscopically with tumor-free margins in all patients, including patients with ampullary carcinoma (n = 24), pancreatic cystadenocarcinoma (n = 4), pancreatic head adenocarcinoma (n = 9), low common bile duct cancer (n = 3), and two patients with chronic pancreatitis with a suspicious mass lesion in the head of pancreas. Mean age of patients was 61 years (range 28 to 70 years). There was a single perioperative mortality. Overall followup rate was 95.1%, with two patients lost to followup at 22 and 36 months. Among the survivors, two patients have metastatic disease and local recurrence developed in one patient. Five-year actuarial survival rates for all patients with malignancy, ampullary adenocarcinoma, pancreatic cystadenocarcinoma, pancreatic head adenocarcinoma, and common bile duct adenocarcinoma are 32%, 30.7%, 33.3%, 19.1%, and 50%, respectively. Presence of microscopic lymph node involvement is associated with poor survival, although operations in the setting of chronic pancreatitis resulted in increased morbidity. CONCLUSIONS: Laparoscopic pancreaticoduodenectomy can be performed with safety and good results in properly selected patients. Localized malignant lesions, irrespective of histopathology, are particularly amenable to this approach.     

未侵犯胰腺被膜及横结肠系膜前叶患者胃癌根治术后生存分析

目的分析胃癌根治术对肿瘤未直接侵犯胰腺被膜及横结肠系膜前叶胃癌患者生存率情况影响。 方法选取2010年8月至2012年8月间在西安凤城医院接受根治术治疗的胃癌患者133例,依据随机数字表法将其分成观察组（66例）与对照组（67例）。观察组术中切除横结肠系膜前叶和胰腺被膜,对照组术中保留横结肠系膜前叶和胰腺被膜。比较两组患者临床资料、手术情况,采用Kaplan-Meier法计算生存率,单因素分析观察组患者术后癌转移的影响因素。 结果观察组患者的手术时间及淋巴结清扫数显著多于对照组,差异有统计学意义（t=3.613、4.222,均P<0.01）;观察组患者术后病理检测显示有5例（7.58%）出现癌转移,转移率在临床分期、浸润深度、淋巴结转移程度、肿瘤前后壁位置方面差异有统计学意义（均P<0.05）。Logistic回归分析显示临床分期、浸润深度、淋巴结转移范围为患者癌转移独立危险因素;两组患者平均生存时间和1、3、5年生存率比较,差异均无统计学意义（t=1.240,χ²=0.086、0.038、0.513,均P>0.05）。 结论淋巴结转移程度高、临床分期晚及肿瘤浸润程度高的胃癌患者越易出现横结肠系膜前叶和胰腺被膜转移,胃癌根治手术中切除横结肠系膜前叶和胰腺被膜对患者手术生存率没有显著影响。